KalVista Pharmaceuticals Inc (NASDAQ: KALV) on Monday, soared 25.71% from the previous trading day, before settling in for the closing price of $11.98. Within the past 52 weeks, KALV’s price has moved between $7.30 and $15.50.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -20.06%. The company achieved an average annual earnings per share of -2.83%. With a float of $38.49 million, this company’s outstanding shares have now reached $49.49 million.
Let’s determine the extent of company efficiency that accounts for 150 employees. In terms of profitability, gross margin is 63.27%, operating margin of -15043.2%, and the pretax margin is -14230.76%.
KalVista Pharmaceuticals Inc (KALV) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of KalVista Pharmaceuticals Inc is 22.58%, while institutional ownership is 88.43%. The most recent insider transaction that took place on Jun 09 ’25, was worth 103,950. In this transaction CHIEF EXECUTIVE OFFICER of this company sold 7,169 shares at a rate of $14.50, taking the stock ownership to the 315,074 shares. Before that another transaction happened on May 23 ’25, when Company’s CHIEF MEDICAL OFFICER sold 2,146 for $11.31, making the entire transaction worth $24,272. This insider now owns 113,026 shares in total.
KalVista Pharmaceuticals Inc (KALV) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -2.83% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 24.62% during the next five years compared to -20.06% drop over the previous five years of trading.
KalVista Pharmaceuticals Inc (NASDAQ: KALV) Trading Performance Indicators
KalVista Pharmaceuticals Inc (KALV) is currently performing well based on its current performance indicators. A quick ratio of 10.44 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.73, a number that is poised to hit -0.81 in the next quarter and is forecasted to reach -3.06 in one year’s time.
Technical Analysis of KalVista Pharmaceuticals Inc (KALV)
Looking closely at KalVista Pharmaceuticals Inc (NASDAQ: KALV), its last 5-days average volume was 2.81 million, which is a jump from its year-to-date volume of 0.7 million. As of the previous 9 days, the stock’s Stochastic %D was 79.89%.
During the past 100 days, KalVista Pharmaceuticals Inc’s (KALV) raw stochastic average was set at 87.77%, which indicates a significant increase from 86.02% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 102.29% in the past 14 days, which was higher than the 63.95% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.50, while its 200-day Moving Average is $10.95. However, in the short run, KalVista Pharmaceuticals Inc’s stock first resistance to watch stands at $16.20. Second resistance stands at $17.34. The third major resistance level sits at $18.77. If the price goes on to break the first support level at $13.63, it is likely to go to the next support level at $12.20. Should the price break the second support level, the third support level stands at $11.06.
KalVista Pharmaceuticals Inc (NASDAQ: KALV) Key Stats
Market capitalization of the company is 748.71 million based on 49,716K outstanding shares. Right now, sales total 0 K and income totals -126,640 K. The company made 0 K in profit during its latest quarter, and -48,510 K in sales during its previous quarter.
